Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc. (ALVR) priced its initial public offering on Jul 30, 2020 at $17.00 per share, within its $16.00–$18.00 range, raising $276.2M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $1.07B. Goodwin Procter advised the company and Latham & Watkins advised the underwriters.

At its 2020 IPO, AlloVir, Inc. (now Kalaris Therapeutics, Inc.) was a late clinical-stage cell therapy company developing off-the-shelf allogeneic virus-specific T cell therapies to treat and prevent viral diseases in patients with T cell deficiencies.

Status

IPO

Ticker

ALVR

Exchange

Nasdaq Global Select

Priced

Jul 30, 2020

IPO price

$17.00

Price range

$16.00–$18.00

Raised

$276.2M

Market cap at IPO price

$1.07B

First filed

Jul 6, 2020

Company counsel

Goodwin Procter

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

NJ

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.